Opus Genetics, Inc. (IRD) Stock

About Opus Genetics, Inc.

Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.

Opus Genetics, Inc. is led by CEO George Magrath, employs 18 people, headquartered in US, publicly traded since 2015.

Opus Genetics, Inc. (IRD) stock trades at $3.47 with a market capitalization of $288.69M. The stock is valued at a negative price-to-earnings (P/E) ratio of -3.23, reflecting a net loss over the last twelve months, a negative price-to-book of -30.15, reflecting negative shareholders' equity, price-to-sales of 34.61. Over the past 52 weeks the stock has ranged between $1.70 and $7.07, and currently trades 50.9% below its 52-week high.

On profitability, Opus Genetics, Inc. generates a return on equity (ROE) of -333.33% (not meaningful, as shareholders' equity is negative), return on capital employed of -59.29%, an operating margin of -278.57%, a net profit margin of -892.36%.

Official website: opusgtx.com

Opus Genetics, Inc. by the numbers, 2019–2025

Between 2019 and 2025 Opus Genetics, Inc. reported revenue of $0 rising to $14.0M. Compounded, revenue has grown —% a year over five years, -29.5% over three, 27.3% over the last twelve months. Net profit fell to $-50.0M.

The most recent net margin is -892.36%. On a trailing twelve-month basis to Jun '26, revenue is $10.0M and net profit $-108.0M.

Borrowings fell from $6.0M to $0, cash from operations was $-35.0M in the latest year, positive in 1 of the last 7.

Return on equity has averaged -280.4% over five years, and was -333.3% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Opus Genetics, Inc. (IRD) — frequently asked questions